Investment Rating - The industry maintains an "Overweight" rating, suggesting a positive outlook for investment opportunities in the sector [6]. Core Insights - The Chinese herbal medicine sector has shown strong performance, with the sub-sector index rising by 2.86%, outperforming other pharmaceutical sub-sectors [2]. - The price governance policies are expected to create a more pronounced differentiation within the industry, favoring companies with competitive advantages [6]. - The upcoming disclosure period for mid-year reports from herbal medicine companies is anticipated to provide insights into their performance, with 43 companies set to report [5]. Market Performance - The Chinese herbal medicine index closed at 6973.18 points, reflecting a 2.86% increase over the past week, while the overall pharmaceutical index rose by 1.05% [2][12]. - The performance of individual companies varied, with ST Xiangxue and Renhe Pharmaceutical leading, while Weikang Pharmaceutical and Xinguang Pharmaceutical lagged [2][17][19]. Valuation Metrics - The price-to-earnings (PE) ratio for the herbal medicine sector is currently at 30.11X, up by 0.85X week-on-week, indicating a relatively high valuation compared to historical levels [3]. - The price-to-book (PB) ratio stands at 2.5X, also reflecting an increase, suggesting that the sector is trading at a premium compared to its historical averages [3]. Supply Chain Insights - The herbal medicine raw material market is experiencing significant inventory pressure, with a slight decline in prices due to weak demand [4]. - The price index for herbal materials has decreased by 0.8% week-on-week, indicating a potential ongoing downward trend in pricing [4]. Investment Recommendations - The report suggests focusing on three main investment themes: price governance, consumption recovery, and state-owned enterprise reform [6][9]. - Specific investment targets include companies with strong R&D capabilities, those less affected by price collection policies, and leading brand herbal medicine firms [10].

Group 1 - The stock price of Shouxiangu (603896) closed at 22.65 yuan on August 22, 2025, an increase of 1.62% from the previous week [1] - The highest intraday price reached 22.92 yuan on August 22, while the lowest was 22.2 yuan on August 20 [1] - The current total market capitalization of Shouxiangu is 4.49 billion yuan, ranking 47th out of 67 in the traditional Chinese medicine sector and 3643rd out of 5152 in the A-share market [1] Group 2 - Shouxiangu provided a maximum pledge guarantee of 30 million yuan for its wholly-owned subsidiary, Jinhua Shouxiangu Pharmaceutical Co., Ltd., in collaboration with Zhejiang Wuyi Rural Commercial Bank [1] - The guarantee is part of a credit facility agreement that allows for financing from August 15, 2025, to May 1, 2027, without the need for counter-guarantees [1] - The company had previously approved a total credit limit of up to 800 million yuan at the 2024 annual shareholders' meeting, allowing for mutual guarantees among the company and its subsidiaries [1] Group 3 - The total amount of external guarantees provided by the listed company and its controlling subsidiaries is 19 million yuan, accounting for 8.27% of the latest audited net assets [1] - Jinhua Shouxiangu Pharmaceutical has a registered capital of 12.999 million yuan, with the company holding 100% equity [1] - As of March 31, 2025, the subsidiary's financial indicators showed total assets of 1.03377 billion yuan, total liabilities of 715.7963 million yuan, net assets of 317.9773 million yuan, operating income of 115.8209 million yuan, and net profit of 7.6159 million yuan [1]

Core Points - The company has entered into a maximum pledge contract with Zhejiang Wuyi Rural Commercial Bank to provide a guarantee for its wholly-owned subsidiary, Shouxiangu Pharmaceutical, with a maximum financing limit of RMB 30 million from August 15, 2025, to May 1, 2027 [1][4] - The company has approved a total credit limit of up to RMB 800 million for the year 2025, allowing for mutual guarantees between the company and its subsidiaries [1][4] - Shouxiangu Pharmaceutical is not a dishonest entity and has no significant issues affecting its debt repayment ability [1][4] Guarantee Details - The guarantee amount is RMB 30 million, covering all creditor rights arising from the contract, including principal, interest, and other related costs [2][4] - The guarantee period is from August 15, 2025, to May 1, 2027, and there is no counter-guarantee provided [4] - The necessity and reasonableness of the guarantee are justified by the stable operating condition of Shouxiangu Pharmaceutical, which has no major defaults or litigation issues [4] Cumulative Guarantee Information - As of the announcement date, the total external guarantees provided by the company amount to RMB 190 million, representing approximately 8.28% of the audited net assets attributable to shareholders as of December 31, 2024 [4]

Core Viewpoint - Zhejiang Shouxiangu Pharmaceutical Co., Ltd. has announced a guarantee for its wholly-owned subsidiary, Jinhua Shouxiangu Pharmaceutical Co., Ltd., amounting to RMB 30 million, to support its financing needs with Wuyi Rural Commercial Bank [1][4]. Group 1: Guarantee Details - The guarantee amount provided is RMB 30 million, with a total guarantee balance of RMB 190 million for the subsidiary [1]. - The guarantee does not include any counter-guarantee [1]. - The total amount of external guarantees by the company is RMB 190 million, which does not exceed 50% of the company's latest audited net assets [1][4]. Group 2: Subsidiary Information - Jinhua Shouxiangu Pharmaceutical Co., Ltd. is a wholly-owned subsidiary of the company, established on August 27, 2003, with a registered capital of RMB 129.99 million [3]. - The subsidiary's main business includes the research and development of traditional Chinese medicine, as well as the sale of various food and health products [3]. Group 3: Financial Performance - As of the first quarter of 2025, the subsidiary reported total assets of RMB 1.03377 billion and total liabilities of RMB 715.80 million, resulting in a net asset value of RMB 317.98 million [3]. - The subsidiary's revenue for the year 2024 was RMB 462.89 million, with a net profit of RMB 2.41 million [3]. Group 4: Necessity and Reasonableness of Guarantee - The guarantee is deemed necessary to support the daily business development of the subsidiary, which is currently stable and does not have any significant litigation or arbitration issues [4]. - The company believes that the risk associated with this guarantee is manageable and does not harm the interests of the company or minority shareholders [4].

证券代码：603896 证券简称：寿仙谷 公告编号：2025-050 债券代码：113660 债券简称：寿 22 转债 浙江寿仙谷医药股份有限公司 关于为全资子公司提供担保的进展公告 近日，因业务发展需要，公司全资子公司寿仙谷药业与浙江武义农村商业银 行股份有限公司（以下简称"武义农商银行"）开展了授信业务。浙江寿仙谷医 药股份有限公司（以下简称"公司"）与浙江武义农村商业银行股份有限公司（以 下简称"武义农商银行"）签定了《最高额质押合同》，为武义农商银行向公司之 全资子公司寿仙谷药业自 2025 年 8 月 15 日至 2027 年 5 月 1 日融资期限内最高 融资限额为人民币 3,000.00 万元的所有融资债权提供最高额质押担保。本次担保 未提供反担保。 （二）内部决策程序 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 担保对象及基本情况 | | 被担保人名称 | | | 金华寿仙谷药业有限公司（以下简称"寿仙 | | --- | --- | --- | --- | --- | | | | 谷药业" ...

Group 1 - The latest stock price of Shouxiangu is 22.29 yuan, an increase of 0.16 yuan from the previous trading day, with a daily high of 22.38 yuan and a low of 22.02 yuan, and a total trading volume of 28,060 hands amounting to 0.62 billion yuan [1] - The company specializes in the research, production, and sales of traditional Chinese medicine health products, with key products including precious Chinese medicinal materials such as Ganoderma and Dendrobium [1] - Shouxiangu has recently led the formulation of the ISO international standard for "Traditional Chinese Medicine - Broken Wall Ganoderma Spore Powder," marking its fourth ISO international standard for Zhejiang-produced famous medicines [1] Group 2 - On August 14, Shouxiangu signed a strategic cooperation agreement with Jiuzhoutong Pharmaceutical, focusing on comprehensive business collaboration in channel construction, supply chain coordination, and market promotion [1] - Jiuzhoutong Pharmaceutical has established 141 high-standard pharmaceutical warehousing and logistics facilities nationwide, providing a stable distribution network foundation for the partnership [1]

Investment Rating - The industry rating is maintained at "Overweight" [8] Core Views - The Chinese medicine sector saw a 3.12% increase last week, with the overall pharmaceutical sector rising by 2.95% [2] - The PE (ttm) for the Chinese medicine sector is 29.58X, up 0.89X week-on-week, while the PB (lf) is 2.45X, up 0.08X week-on-week [3] - The "Thousand-Year Herbal" initiative aims to establish a comprehensive communication system for the entire lifecycle of Chinese medicine, focusing on resource protection, quality control, and technological innovation [5] - The recent implementation of centralized procurement for Chinese medicine pieces is expected to drive industry standardization and enhance competitive advantages for companies with strong management and innovation capabilities [6] Market Performance - The Chinese medicine II index closed at 6845.97 points, reflecting a 3.12% increase, while the chemical pharmaceuticals index rose by 5.01% [2][14] - The performance of leading companies includes Qizheng Tibetan Medicine and Zhongsheng Pharmaceutical, while companies like Qidi Pharmaceutical and Kangmei Pharmaceutical lagged behind [2] Valuation - The Chinese medicine sector's PE (ttm) is at 29.58X, which is at the 35.13% percentile since 2013, while the PB (lf) is at 2.45X, at the 8.52% percentile since 2013 [3] Supply Chain Insights - The market for Chinese medicinal materials is currently balanced, with the price index remaining stable despite fluctuations in supply due to extreme weather [4] Investment Suggestions - The report suggests focusing on three main investment themes: price governance, consumption recovery, and state-owned enterprise reform [11] - Companies with strong R&D capabilities and unique products are recommended, along with those less affected by centralized procurement [12]

证券代码：603896 证券简称：寿仙谷 公告编号：2025-049 债券代码：113660 债券简称：寿22转债 浙江寿仙谷医药股份有限公司 2025年7月31日 ■ 上述产品备案成功不会对公司近期的生产经营产生重大影响，但有利于进一步补充完善公司的产品品 类，丰富公司的产品线，提升公司在保健食品领域的竞争力，符合公司布局大健康产业的战略规划，为 企业持续发展打下扩容基础。 特此公告。 浙江寿仙谷医药股份有限公司董事会 关于全资子公司完成国产保健食品备案的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 近日，浙江寿仙谷医药股份有限公司（以下简称"公司"）全资子公司金华寿仙谷药业有限公司的"寿仙 品牌破壁灵芝孢子粉"产品完成了国产保健食品备案工作，并获得浙江省市场监督管理局发放的国产保 健食品备案凭证。具体情况如下： ...

Group 1 - The company Shouxiangu announced that its wholly-owned subsidiary, Jinhua Shouxiangu Pharmaceutical Co., Ltd., has completed the domestic health food filing for its "Shouxiangu Brand Broken Wall Ganoderma Spore Powder" product [1] - The product has received the domestic health food filing certificate issued by the Zhejiang Provincial Market Supervision Administration [1]

| 证券代码：603896 | 证券简称：寿仙谷 | | 公告编号：2025-049 | | --- | --- | --- | --- | | 债券代码：113660 | 债券简称：寿 22 | 转债 | | 浙江寿仙谷医药股份有限公司 2025 年 7 月 31 日 近日，浙江寿仙谷医药股份有限公司（以下简称"公司"）全资子公司金华 寿仙谷药业有限公司的"寿仙品牌破壁灵芝孢子粉"产品完成了国产保健食品备 案工作，并获得浙江省市场监督管理局发放的国产保健食品备案凭证。具体情况 如下： | 产品名称 | 寿仙品牌破壁灵芝孢子粉 | | --- | --- | | 保健功能 | 有助于增强免疫力 | | 备案号 | 食健备 G202533002302 | | 备案人 | 金华寿仙谷药业有限公司 | | 备案人地址 | 浙江省金华市武义县壶山街道商城路 10 号 | | 备案结论 | 按照《中华人民共和国食品安全法》《保健食品注册与备 | | | 案管理办法》等法律、规章的规定，予以备案。 | 上述产品备案成功不会对公司近期的生产经营产生重大影响，但有利于进一 步补充完善公司的产品品类，丰富公司的产品线，提升公司 ...